CPT1A and breast carcinoma: A 24 hr incubation with 100 ng/ml of recombinant human PRL significantly increased CPT1A mRNA levels by 1.8- and 1.6-fold in MCF-7 and MDA-MB-231 breast cancer cells, respectively (Figure 1C; p < 0.0001 and p < 0.001, respectively) compared to untreated controls.